Incyte Corp. (INCY) | Finance information

Revenue & Earnings

Balance Sheet

Share Statistics

Compare to

Market

Industry

Market Cap The market value of the company. It's calculated by multiplying the share price by the number of outstanding shares.	$16.1 Billion
Enterprise Value A measure of a company's total value. This includes market cap, cash, and debt.	$12.9 Billion
Dividend Yield Yearly payout to shareholders per share. The percentage indicates the payout in relation to the share price.	$0.00 (0.0%)
1 Year Return Profit or loss of share price change plus dividend yield.	-6.3%
52-Week High Highest share price in the last 52 weeks.	$86.29
52-Week Low Lowest share price in the last 52 weeks.	$65.07
Beta Beta indicates the volatility of a stock compared to the market. Higher beta means more volatile and thus potentially higher risk and return.	0.57
Outstanding Shares The number of shares the company has issued and are held by stockholders.	223 Million
Avg 30 Day Volume The number of shares traded in the last 30 days.	1.42 Million

Valuation

Compare to

Market

Industry

P/E Ratio Ratio between share price and earnings per share. A low ratio could indicate that the stock is undervalued or investors aren't expecting high growth. A high ratio could indicate that the stock is overvalued or investors are expecting high growth.	47.29
PEG The ratio between the P/E ratio and the growth rate of the company's earnings per share in the last twelve months. A lower PEG could mean that a stock is undervalued.	-49.81
Earnings per Share Earnings divided by outstanding shares. Higher EPS indicates greater value.	$1.52
Price to Sales Ratio Market cap divided by the revenue in the most recent year.	4.68
Price to Book Ratio Price to Book Ratio is the Market cap divided by the Book value of the company	3.7
Enterprise Value to Revenue Enterprise value divided by revenue	3.8
Enterprise Value to EBIT Enterprise Value divided by EBIT	21.53
Total Debt to Enterprise Value Total debt divided by enterprise value	0.0
Debt to Equity A higher ratio indicates a higher risk. However, the ratio is difficult to compare between industries where common amounts of debt vary.	0.01

Profitability

Compare to

Market

Industry

Revenue Revenue is the sum of all cash flow into the company.	$3.39 Billion
Gross Profit Gross profit is the profit after subtracting the costs of making and selling its products or the costs of providing its services. It indicates the efficiency of using their resources to produce goods or services.	$3.19 Billion
EBIT Earnings before tax and interest payments.	$600 Million
Net Income Net Income is the profit after all expenses have been deducted from the total revenue.	$341 Million
Profit Margin Net income divided by revenue of the last 4 quarters. It indicates the company's profitability.	10.04%
Quarterly Earnings Growth (YoY) The rate at which the company's net income has increased to the same quarter one year ago.	-95.0%
Return on Equity Equity divided by market cap.	7.80%
Return on Assets Indicates a company's profitability in relation to its total assets.	5.83%
Return on Invested Capital Return on invested capital (ROIC) is net income after dividends divided by the sum of debt and equity. It shows how effective a company is at turning capital invested by shareholders and other debtholders into profits.	12.80%

Insider trades

Q2 2022 Q3 2022 Q4 2022 Q1 2023

About Incyte Corp.

CEO: Paul Friedman

Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)

Similar stocks

AMGEN Inc.

Ligand Pharmaceuticals, Inc. - Class B

AVEO Pharmaceuticals Inc

CTI BioPharma Corp

News

SVB Leerink Upgrades Incyte to Market Perform

https://www.investing.com/news/pro/svb-leerink-upgrades-incyte-to-market-perform-432SI-3039445

Investing.com, 3 days ago

FDA Approves Incyte''s Zynyz For Skin Cancer Treatment

WASHINGTON (dpa-AFX) - Incyte (INCY) said that the U.S. Food and Drug Administration has approved Zynyz (retifanlimab-dlwr) for the treatment of adults with ...

Finanz Nachrichten, 4 days ago

Incyte says mid-stage trial for vitiligo therapy met main goal (NASDAQ:INCY)

Incyte (INCY) traded ~5% higher on Monday after announcing that its oral JAK1 inhibitor povorcitinib met the main goal in a Phase 2 trial for adults with vit...

Seeking Alpha, 7 days ago